VMD (Viemed Healthcare, Inc. Common Shares)
Insider Trading Activity
Every open-market purchase and sale reported by VMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-26 | William Frazier | Chief Medical Officer | MIXED | — | — |
| 2026-06-26 | Timothy Smokoff | Director | Sell | — | — |
| 2026-03-20 | Michael Moore | President | Sell | — | — |
| 2026-02-02 | Trae Fitzgerald | Chief Financial Officer | MIXED | — | — |
| 2026-02-02 | Jerome Cambre | Vice President of Sales | MIXED | — | — |
| 2026-02-02 | Michael Moore | President | MIXED | — | — |
| 2026-02-02 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2026-02-02 | William Frazier | Chief Medical Officer | MIXED | — | — |
| 2026-02-02 | WILLIAM TODD ZEHNDER | Chief Operating Officer | MIXED | — | — |
| 2026-02-02 | Jeremy Trahan | General Counsel | MIXED | — | — |
| 2026-01-23 | WILLIAM TODD ZEHNDER | Chief Operating Officer | MIXED | — | — |
| 2026-01-23 | Trae Fitzgerald | Chief Financial Officer | MIXED | — | — |
| 2026-01-23 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2026-01-23 | Jerome Cambre | Vice President of Sales | MIXED | — | — |
| 2026-01-23 | William Frazier | Chief Medical Officer | MIXED | — | — |
| 2026-01-23 | Michael Moore | President | MIXED | — | — |
| 2026-01-23 | Jeremy Trahan | General Counsel | MIXED | — | — |
| 2026-01-21 | Michael Moore | President | MIXED | — | — |
| 2026-01-21 | WILLIAM TODD ZEHNDER | Chief Operating Officer | MIXED | — | — |
| 2026-01-21 | William Frazier | Chief Medical Officer | A | — | — |
| 2026-01-21 | Jeremy Trahan | General Counsel | MIXED | — | — |
| 2026-01-21 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2026-01-21 | Jerome Cambre | Vice President of Sales | MIXED | — | — |
| 2026-01-21 | Trae Fitzgerald | Chief Financial Officer | MIXED | — | — |
| 2025-08-25 | Jeremy Trahan | General Counsel | MIXED | — | — |
| 2025-08-20 | Sabrina Heltz | Director | M | — | — |
| 2025-08-20 | Timothy Smokoff | Director | M | — | — |
| 2025-08-20 | Randy E. Dobbs | Director | M | — | — |
| 2025-08-20 | Nitin Kaushal | Director | M | — | — |
| 2025-08-14 | Jerome Cambre | Vice President of Sales | Sell | — | — |
| 2025-08-13 | Michael Moore | President | D | — | — |
| 2025-08-13 | Michael Moore | President | Sell | — | — |
| 2025-07-01 | Nitin Kaushal | Director | MIXED | — | — |
| 2025-07-01 | Michael Moore | President | MIXED | — | — |
| 2025-06-30 | Nitin Kaushal | Director | MIXED | — | — |
| 2025-03-17 | Timothy Smokoff | Director | Sell | — | — |
| 2025-01-31 | Jeremy Trahan | General Counsel | MIXED | — | — |
| 2025-01-31 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2025-01-31 | Trae Fitzgerald | Chief Financial Officer | MIXED | — | — |
| 2025-01-31 | William Frazier | Chief Medical Officer | MIXED | — | — |
| 2025-01-31 | WILLIAM TODD ZEHNDER | Chief Operating Officer | MIXED | — | — |
| 2025-01-31 | Michael Moore | President | MIXED | — | — |
| 2025-01-31 | Jerome Cambre | Vice President of Sales | MIXED | — | — |
| 2025-01-23 | Trae Fitzgerald | Chief Financial Officer | MIXED | — | — |
| 2025-01-23 | WILLIAM TODD ZEHNDER | Chief Operating Officer | MIXED | — | — |
| 2025-01-23 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2025-01-23 | Jerome Cambre | Vice President of Sales | MIXED | — | — |
| 2025-01-23 | Michael Moore | President | MIXED | — | — |
| 2025-01-22 | Casey Hoyt | Chief Executive Officer | MIXED | — | — |
| 2025-01-22 | Michael Moore | President | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 2,335,407 | — |
| — | President | 1,880,134 | — |
| — | Chief Operating Officer | 390,309 | — |
| — | Director | 142,575 | — |
| — | Director | 125,490 | — |
| — | Chief Financial Officer | 108,903 | — |
| — | Vice President of Sales | 106,443 | — |
| — | Director | 80,518 | — |
| — | Director | 76,651 | — |
| — | Chief Medical Officer | 73,214 | — |
| — | Director | 67,491 | — |
| — | General Counsel | 46,492 | — |
| — | General Counsel | 2,261 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VMD quote page; the site-wide leaderboard is on the insider transactions hub.